$XBI $140.95 (+0.12%) 📈
COVID:
$ARCT (+12.72%) - Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
$MRNA (+6.95%) - Moderna Provides COVID-19 Vaccine Supply Update
PIPELINE:
$AYLA (+2.36%) - Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
$CALA (-44.60%) - Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
$ENDP (+4.18%) - Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States
$PAND (+47.74%) - Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
$PRVB (+7.79%) - Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals